PSB-202 is under clinical development by Qilu Puget Sound Biotherapeutics and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PSB-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PSB-202 is under development for the treatment of follicular lymphoma, chronic lymphocytic leukemia, waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), marginal zone B-cell lymphoma, mantle cell lymphoma, extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue or MALT-lymphoma). The drug candidate consisting of two engineered monoclonal antibodies Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107). The drug candidate is a monoclonal antibody and developed based on MabPair platform. MabPair platform produces mixture of antibodies that are targeting multiple molecules and pathways. It acts by targeting CD20 and CD37.
Qilu Puget Sound Biotherapeutics overview
Qilu Puget Sound Biotherapeutics (Sound Biologics) is a biotech company. The company develops treatments for cancer.
For a complete picture of PSB-202’s drug-specific PTSR and LoA scores, buy the report here.